Early events in proton pump inhibitor-associated exacerbation of corpus gastritis

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 2, 2003, Pages 193-200

  Graham, D Y ^a   Opekun, A R ^a   Yamaoka, Y ^a   Osato, M S ^a   El Zimaity, H M T ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 8; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERADICATION THERAPY; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LONG TERM CARE; MALE; PRIORITY JOURNAL; SCORING SYSTEM; STOMACH ANTRUM; STOMACH BIOPSY; STOMACH MUCOSA; VISUAL ANALOG SCALE;

ADULT; ANTI-ULCER AGENTS; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; OMEPRAZOLE; PROTON PUMPS;

EID: 0037314881     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01400.x     Document Type: Article

References (56)

1. Tarpila S, Kekki M, Samloff IM, Sipponen P, Siurala M. Morphology and dynamics of the gastric mucosa in duodenal ulcer patients and their first-degree relatives. HepatoGastroenterology 1983; 30: 198-201.
2. Siurala M. Gastritis, its fate and sequelae. Ann Clin Res 1981: 13: 111-3.
3. Siurala M, Sipponen P, Kekki M. Chronic gastritis: dynamic and clinical aspects. Scand J Gastroenterol Suppl 1985; 109: 69-76.
4. Siurala M, Salmi HJ. Long-term follow-up of subjects with superficial gastritis or a normal gastric mucosa. Scand J Gastroenterol 1971; 6: 459-63.
5. Villako K, Kekki M, Tamm A, Savisaar E. Development and progression of chronic gastritis in the antrum and body mucosa: results of long-term follow-up examinations. Ann Clin Res 1986; 18: 121-3.
6. Kimura K. Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach. Gastroenterology 1972; 63: 584-92.
7. Tatsuta M, Iishi H, Okuda S. Location of peptic ulcers in relation to antral and fundal gastritis by chromoendoscopic follow-up examinations. Dig Dis Sci 1986; 31: 7-11.
8. Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology 1997; 113: 1983-91.
9. Graham DY. Helicobacter pylori infection is the primary cause of gastric cancer. J Gastroenterol 2000; 35(Suppl. 12): 90-7.
10. Kekki M, Saukkonen M, Sipponen P, Varis K, Siurala M. Dynamics of chronic gastritis in the remnant after partial gastrectomy for duodenal ulcer. Scand J Gastroenterol 1980; 15: 509-12.
11. Meikle DD, Taylor KB. Truelove SC, Whitehead R. Gastritis, duodenitis, and circulating levels of gastrin in duodenal ulcer before and after vagotomy. Gut 1976; 17: 719-28.
12. Peetsalu A, Maaroos HI, Sipponen P, Peetsalu M. Long-term effect of vagotomy on gastric mucosa and Helicobacter pylori in duodenal ulcer patients. Scand J Gastroenterol Suppl 1991; 186: 77-83.
13. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989; 96: 615-25.
14. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356-70.
15. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22.
16. Meining A, Kiel G, Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Aliment Pharmacol Ther 1998; 12: 735-40.
17. Stolte M, Bethke B. Elimination of Helicobacter pylori under treatment with omeprazole. Z Gastroenterol 1990; 28: 271-4.
18. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
19. Meining A, Bosseckert H, Caspary WF, Nauert C, Stolte M. H2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients. Aliment Pharmacol Ther 1997; 11: 729-34.
20. Moayyedi P, Wason C, Peacock R, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000; 5: 206-14.
21. Stolte M, Meining A, Schmitz JM, Alexandridis T, Seifert E. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998; 12: 247-53.
22. Stolte M, Meining A, Koop H, Seifert E. Eradication of Helicobacter pylori heals atrophic corpus gastritis caused by long-term treatment with omeprazole. Virchows Arch 1999; 434: 91-4.
23. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995; 90: 1401-6.
24. Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000; 46: 615-21.
25. Berstad AE, Hatlebakk JG, Maartmann-Moe H, Berstad A, Brandtzaeg P. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut 1997; 41: 740-7.
26. Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 707-17.
27. Furuta T, Baba S, Takashima M, et al. Effect of Helicobacter pylori infection on gastric juice pH. Scand J Gastroenterol 1998; 33: 357-63.
28. Geboes K, Dekker W. Mulder CJ, Nusteling K. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther 2001; 15: 1819-26.
29. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels. Aliment Pharmacol Ther 1999; 13: 1343-6.
30. Uemura N, Okamoto S, Yamamoto S, et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. Aliment Pharmacol Ther 2000; 14: 1345-52.
31. van Grieken NC, Meijer GA, Weiss MM, et al. Quantitative assessment of gastric corpus atrophy in subjects using omeprazole: a randomized follow-up study. Am J Gastroenterol 2001; 96: 2882-6.
32. Genta RM. Acid suppression and gastric atrophy: sifting fact from fiction. Gut 1998; 43(Suppl. 1): S35-8.
33. Freston JW. Antagonist: should we eradicate Helicobacter pylori before long term antireflux therapy? Gut 2001; 49: 616-7.
34. Labenz J. Protagonist: should we eradicate Helicobacter pylori before long term antireflux therapy? Gut 2001; 49: 614-6.
35. Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995; 36: 12-6.
36. Graham DY, Genta R, Evans DG, et al. Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole. Am J Gastroenterol 1996; 91: 2120-4.
37. Suzuki M, Suzuki H, Kitahora T, et al. Proton pump inhibitor modifies inflammatory reaction in human gastric mucosa infected by Helicobacter pylori. Aliment Pharmacol Ther 2002; 16(Suppl. 2): 229-34.
38. Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K, Graham DY. Relation between clinical presentation. Helicobacter pylori density, interleukin 1beta and 8 production, and cagA status. Gut 1999; 45: 804-11.
39. El-Zimaity HM, Ota H, Scott S, Killen DE, Graham DY. A new triple stain for Helicobacter pylori suitable for the autostainer: carbol fuchsin/Alcian blue/hematoxylin-eosin. Arch Pathol Lab Med 1998; 122: 732-6.
40. El-Zimaity HM, Graham DY, Al-Assi MT, et al. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol 1996; 27: 35-41.
41. Graham DY, Hoffman J, El-Zimaity HM, Graham DP, Osato M. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 935-8.
42. Yamaoka Y, Kita M, Kodama T. Sawai N, Kashima K, Imanishi J. Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains. Gut 1997; 41: 442-51.
43. Genta RM, Graham DY. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointest Endosc 1994; 40: 342-5.
44. Ota H, Genta RM. Morphological characterization of the gastric mucosa during infection with H. pylori. In: Ernst P, Michetti P, Smith PD, eds. The Immunobiology of H. pylori from Pathogenesis to Prevention. Philadelphia: Lippincott-Raven. 1997: 15-28.
45. El-Zimaity HM, Ota H, Graham DY, Akamatsu T, Katsuyama T. Patterns of gastric atrophy in intestinal type gastric carcinoma, Cancer 2002; 94: 1428-36.
46. El-Zimaity HMT, Gutierrez O. Kim JG. et al. Geographic differences in the distribution of intestinal metaplasia in duodenal ulcer patients. Am J Gastroenterol 2001; 96: 666-72.
47. Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic GERD Study Group. Gastroenterology 1999; 117: 319-26.
48. Solcia E, Fiocca R, Havu N. Dalvag A, Carlsson R, Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992; 51(Suppl. 1): 82-92.
49. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9.
50. Correa P, Cuello C. Fajardo LF, Haenszel W, Bolanos O, de Ramirez B. Diet and gastric cancer: nutrition survey in a high-risk area. J Natl Cancer Inst 1983; 70: 673-8.
51. Correa P. Diet modification and gastric cancer prevention. J Natl Cancer Inst Monogr 1992: 75-8.
52. El Zimaity HM, Ramchatesingh J. Saeed MA. Graham DY. Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol 2001: 54: 679-83.
53. Uemura N, Okamoto S. Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
54. Miehlke S, Hackelsberger A, Meining A. et al. Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori. Br J Cancer 1998; 78: 263-6.
55. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report, Aliment Pharmacol Ther 2002; 16: 167-80.
56. Graham DY, Dixon MF. Acid secretion, Helicobacter pylori, and peptic ulcer disease. In: Graham DY, Genta RM, Dixon MF, eds. Gastritis. Philadelphia: Lippincott Williams & Wilkins. 1999: 177-88.